Table 2 Clinical features of methotrexate-associated T-cell lymphoproliferative disorder of angioimmunoblastic T-cell lymphoma type (MTX-AITL) compared to angioimmunoblastic T-cell lymphoma (AITL)

From: Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases

Variable

MTX-AITL (n = 19)

AITL (n = 213)

P

Sex (M/F)

13/6

137/76

0.81

Age (median[range])

72 (57–85)

67(34–91)

0.0037

PS > 1

5/19 (26%)

75/209 (36%)

0.46

Stage III/IV

16/18 (89%)

189/211 (89%)

–

B symptom

11/19 (58%)

123/205 (60%)

–

Extranodal site > 1

4/18 (22%)

45/200 (23%)

–

LDH > normal

10/19 (53%)

157/209 (75%)

0.054

IPI HI/H

11/17 (65%)

138/199 (69%)

0.79

EBV in background

17/19 (89%)

55/166 (67%)

0.064

  1. AITL angioimmunoblastic T-cell lymphoma, EBV Epstein-Barr virus, F female, H high, HI high-intermediate, IPI international prognostic index, LDH lactate dehydrogenase, M male, MTX-AITL MTX-associated lymphoproliferative disorder of AITL type, PS performance status
Back to article page